July 2018
Volume 59, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2018
Fluocinolone Acetonide (0.19 mcg/day) Intravitreal Implant and Improved Treatment Burden for Patients with Diabetic Macular Edema (DME)
Author Affiliations & Notes
  • Matthew Byun
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States
    Vitreoretinal Disease, Cincinnati Eye Institute, Cincinnati, Ohio, United States
  • Christopher D Riemann
    Vitreoretinal Disease, Cincinnati Eye Institute, Cincinnati, Ohio, United States
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States
  • James Osher
    Vitreoretinal Disease, Cincinnati Eye Institute, Cincinnati, Ohio, United States
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States
  • Yogin Patel
    Vitreoretinal Disease, Cincinnati Eye Institute, Cincinnati, Ohio, United States
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States
  • Footnotes
    Commercial Relationships   Matthew Byun, Alimera Sciences (R); Christopher Riemann, Alimera Sciences (C); James Osher, None; Yogin Patel, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4820. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Matthew Byun, Christopher D Riemann, James Osher, Yogin Patel; Fluocinolone Acetonide (0.19 mcg/day) Intravitreal Implant and Improved Treatment Burden for Patients with Diabetic Macular Edema (DME). Invest. Ophthalmol. Vis. Sci. 2018;59(9):4820.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Studies have shown that patients with diabetic macular edema (DME) have significantly greater treatment burden than non-DME patients due to frequent total health care visits.[i] Frequent injections and office visits can have a substantial impact on patient adherence and quality of life. This analysis of real-world data assesses the impact of a 0.19 mg fluocinolone acetonide (FAc) implant on treatment burden in patients with DME.

Methods : This study is a single-center retrospective chart review of 30 eyes (23 patients) that received a single intravitreal injection of 0.19 mg FAc implant (ILUVIEN, Alimera Science Inc., Alpharetta, GA). Data was collected for a 12-month period pre- and post-FAc injection. Primary outcomes included the number of injections and ophthalmology-related office visits. Secondary outcomes included visual acuity (VA), intraocular pressure (IOP) and central sub-field thickness (CSFT) on optical coherence tomography (OCT).

Results : The injection frequency significantly decreased from one injection every 2.6 months pre-FAc to one injection every 8.8 months post-FAc (P<0.001). 63% of the eyes did not require additional injections post-FAc. The mean number of ophthalmology-related office visits also significantly decreased from 12.7 visits pre-FAc to 9.3 visits post-FAc (P<0.001). At 12 months post-FAc, the mean VA and CSFT showed a mild improvement. In regards to IOP events, 37% of the eyes required additional IOP lowering drops post-FAc. No eyes required an incisional glaucoma surgery post-FAc.

Conclusions : Our results showed that a single intravitreal injection of 0.19 mg FAc implant significantly decreased the treatment burden while maintaining/improving the VA and the CSFT. Specifically, both the frequency of injections and office visits decreased significantly post-FAc. IOP events were in-line with FAME trial and other real-world data with zero eyes requiring an incisional glaucoma surgery.

[i] Kiss, S., Chandwani, H. S., Cole, A. L., Patel, V. D., Lunacsek, O. E., & Dugel, P. U. (2016, December 07). [Full text] Comorbidity and health care visit burden in working-age commercially i | OPTH. Retrieved November 12, 2017, from https://www.dovepress.com/comorbidity-and-health-care-visit-burden-in-working-age-commercially-i-peer-reviewed-fulltext-article-OPTH

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×